IGIM
HZNP

I.G. Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

I.G. Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-150,000
Closed -$1.78M – 506
2017
Q2 		$1.78M Buy
150,000
+25,000
+20% +$311K 0.01% 273
2017
Q1 		$1.85M Buy
+125,000
New +$2.02M 0.01% 271

Other funds holding HZNP

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

I.G. Investment Management's HZNP Position: Q3 2017 in Review

I.G. Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2017, closing a stake of 150,000 shares — an estimated $1.78M sold.

I.G. Investment Management first reported a position in HZNP in Q1 2017 and held it in 2 quarters. The position peaked at $1.85M in Q1 2017. 181 funds tracked by Wall St. Rank hold HZNP as of Q3 2017.

  • I.G. Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • I.G. Investment Management sold 150,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2017, an estimated $1.78M.
  • I.G. Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and held it in 2 quarters.
  • I.G. Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.85M in Q1 2017.
  • 181 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2017.

Based on I.G. Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.